Additionally, ellagic acid-mediated LOXL2 inhibition was more effective than tumor cell-intrinsic LOXL2 knockdown at reducing tumor growth when combined with anti-PD-L1, eliciting an initial reduction in tumor size that was sustained throughout the course of treatment (Fig. 3a vs. Supplementary Fig. 5a). Here, LOXL2 is linked to neoplasm.